Yan Zhang’s Post

Affinity, in-pen assays, in-channel assays, sequential assays, cell export, etc - on the same cell in a single chip? If you want to know more - join Vincent Pai and the team at PEGS conference in Boston! #antibodydiscovery #antibodyblocking #affinity #vaccinedevelopment #neutralizingantibodies #IgG #IgM

Get a sneak peek at the latest #validationstudies from the Generative Biologics Platform here 👇

Unlocking New Possibilities in Precision Medicine The world of pharmaceuticals is evolving rapidly, and one of the most exciting breakthroughs is the rise of Antibody-Drug Conjugates (ADCs). ADCs are an innovative class of targeted therapy that combines the precision of monoclonal antibodies with the potent effects of cytotoxic drugs. 🔬 Targeted Delivery: ADCs work by selectively delivering toxic drugs to cancer cells, sparing healthy cells. This targeted approach enhances efficacy while minimizing side effects, leading to better patient outcomes. 💡 Versatility and Adaptability: ADCs offer a flexible platform that can be tailored for different types of cancers and diseases. This adaptability opens up new avenues for personalized medicine, allowing for more precise treatment plans. 💼 Business Impact: For companies in the pharmaceutical industry, ADCs present significant growth opportunities. As demand for targeted therapies rises, those who invest in ADC research and development will be at the forefront of innovation. See how the nCounter® ADC Development Panel can help answer complex questions critical for the success of Antibody Drug Conjugates throughout discovery, pre-clinical and clinical development. https://lnkd.in/g7ugBuxZ #Pharmaceuticals #ADCs #Biotechnology #PrecisionMedicine #Innovation #nanostring #nCounter

Upcoming Webinar: Building Broader B Cell Diversity for Better Monoclonal Antibody Discovery. Join us Feb 28 at to learn how researchers leverage optofluidic technology to perform upfront, in-depth functional characterization, and how the technology enables rapid discovery of high value monoclonal antibodies across many different species and B cell sources. Get the full information on our blog: https://hubs.ly/Q02lp50v0

Webinar tomorrow!! Still using hybridoma? Sequencing and re-expressing thousands of useless hits? You don’t need to! Register below and find out why Beacon is both the present AND future gold standard in antibody discovery! #bruker #beacon #antibodydiscovery #singlecellanalysis #nextgenai

Get a sneak peek at the validation studies This week, we want to sneak a peek at our #validationstudies of the Generative Biologics platform. During the development of our models, we assessed their ability to optimize an #antibody based on the 3D complex. We conducted an in silico study using Thymic Stromal Lymphopoietin (TSLP) and the anti-TSLP antibody Tezepelumab (PDB: 5j13). Here’s what we’ve accomplished: Novel CDRH3 Sequences: We masked the CDRH3 region of the antibody in the initial complex. Using our in-house Ab-specific protein language model (PLM), we generated 1,000 novel CDRH3 sequences. In Silico Analysis: -We folded the optimized antibody sequences and aligned them with the real binder. -Through RMSD filtering, which compares new structures to the real binder, we identified 21 promising hits with similar geometry. -Our calculations showed that 7 of these antibodies exhibited binding energy profiles comparable to or better than the initial binder. This brief study demonstrates how models used in #GenerativeBiologics can accelerate your research. More detailed platform validation, including in vitro testing results, will be available in our upcoming article. Stay tuned! For now, stay up to date by visiting: https://bit.ly/4e1wHXD

For those of you who missed my presentation at AE&T or would like to see the slides again, here is my presentation: "Antibodies to Watch in 2024: mid year update and key development metrics"

Join us Feb 28 the upcoming Webinar to learn how Beacon technology enables raipd discovery of monicolonal antibodies across different species and B cell sources!!!

Do you know that Cerba Research was one of the first organisations in Europe to offer multispectral multiplex IHC services to pharmaceutical and biotechnology companies? Learn more about what technical advantage offers Multiplex Immunoflorescence (IF) and how Cerba Research uses solid tumor analytical validation of T-regulatory immunohistochemistry multiplex for clinical studies. Check more here: https://lnkd.in/ep76xrjK #MultiplexImmunofluorescence #IHC #TransformingResearch #AdvancingHealth

📢 Exciting News Alert! 🚀 Our latest research has been published as a preprint! 📄🔬 Check out our findings on "Introducing a novel approach to enhance antibody design for more effective target binding. Exciting developments await in the realm of targeted therapeutics!!" join the discussion. Your feedback is invaluable! #research #preprint